Drug treatments of cortical neuronal cultures were performed using 20 μM (Sigma-Aldrich 250401) diluted in dimethyl sulfoxide (DMSO) for 2 hours. For third-instar larva, drugs were fed in 10% sucrose solution supplemented with either 1 mM TBA (Sigma-Aldrich, SML0044) or 800 μM Ciliobrevin D and DMSO for 30 min and 2 hours, respectively.
Sml0044
Manufactured by Merck Group
The SML0044 is a laboratory equipment product manufactured by Merck Group. It is a precision instrument designed for scientific and research applications. The core function of the SML0044 is to perform controlled and accurate measurements or analyses. Further details on the intended use or specific applications of this product are not available.
Automatically generated - may contain errors
Lab products found in correlation
Mg132, by Merck Group (1 mentions)
M7449, by Merck Group (1 mentions)
Tubastatin a, by Merck Group (1 mentions)
Bms 303141, by Merck Group (1 mentions)
Sml0784, by Merck Group (1 mentions)
C104450, by Merck Group (1 mentions)
3 methyladenine, by MedChemExpress (1 mentions)
Bafilomycin a1, by MedChemExpress (1 mentions)
As1842856, by MedChemExpress (1 mentions)
Ex527, by MedChemExpress (1 mentions)
3 protocols using sml0044
1
Cortical Neuron and Larva Drug Treatments
2
Investigating Tau Ubiquitination and HDAC Inhibition
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
BMS 303141 (BMS), Tubastatin A (TubA), MG-132 and cycloheximide were obtained from Sigma-Aldrich (SML0784, SML0044, M7449, and C104450, respectively). MG-132 (20 µM) was added to fully differentiated cells 4 h prior to protein extraction. For ubiquitinated Tau MG-132 (17.5 µM) was added to HEK293 transfected cells 15 h prior to immunoprecipitation. Treatment of TubA, (2 µM) for 24 h alone or together with MG-132 (20 µM) for the last 4 h were added to fully differentiated cells, prior to protein extraction. BMS (1 µM) was added to fully differentiated cells for 72 h prior to cells fixation and immunofluorescence analysis.
3
Evaluating SIRT1, HDAC6, and FOXO1 Modulation in Hepa 1-6 Cells
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For SIRT1 inhibition, Hepa 1–6 cells were treated for 12 and 24 hours with 0.1 mmol/L OA and 10 μmol/L EX-527 (HY-15452; MedChemExpress, Monmouth Junction, NJ). For HDAC6 inhibition, Hepa 1–6 cells were treated for 6, 12, and 24 hours with 0.1 mmol/L OA and 40 nmol/L TBA (SML0044; Sigma-Aldrich). For FOXO1 inhibition, the cells were treated for 6 hours with the specific inhibitor AS1842856 (HY-100596; MedChemExpress) at a final concentration of 0.25 μmol/L. For autophagy inhibition, Hepa 1–6 cells were treated for 12 hours with 0.1 mmol/L OA and 10 nmol/L bafilomycin A1 (HY-100558; MedChemExpress) or with 0.1 mmol/L OA and 2 mmol/L 3-methyladenine (HY-19312; MedChemExpress). For RNA knockdown of Atg7, mouse small interfering RNA of Atg7 was ordered from Ribobio Co (Guangzhou, China) and the related experiment was conducted according to the manufacturer’s instructions.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!